NCT03431428 is a Phase 3 clinical trial of transanal surgery in Almost-cCR, sponsored by Zhang Rui.

Who is sponsoring NCT03431428?

NCT03431428 is sponsored by Zhang Rui.

What drugs are being tested in NCT03431428?

Interventions in NCT03431428: transanal surgery, Miles surgery, Preoperative chemoradiotherapy.

What condition does NCT03431428 study?

NCT03431428 studies Almost-cCR, Surgery, Rectal Cancer.

Is NCT03431428 still recruiting?

NCT03431428 is currently status unknown. Last updated 13 February 2018.

Last reviewed 2018-02-13 · How we verify

NCT03431428

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparison of Short-term Efficacy and Long-term Prognosis for Reduction Surgery and Radical Resection in Almost-cCR Rectal Cancer Patients

Status unknown Phase 3 Last updated 13 February 2018

What this trial tests

Phase 3 trial testing transanal surgery in Almost-cCR in 477 participants. Status unknown.

Timeline

1 January 2018

Primary endpoint
1 January 2020

31 December 2022

Quick facts

Lead sponsor	Zhang Rui
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	477
Start date	1 January 2018
Primary completion	1 January 2020
Estimated completion	31 December 2022
Sites	1 location across China

Drugs / interventions tested

transanal surgery
Miles surgery
Preoperative chemoradiotherapy — full drug profile →

Conditions studied

Almost-cCR — all drugs for Almost-cCR →
Surgery — all drugs for Surgery →
Rectal Cancer — all drugs for Rectal Cancer →

Sponsor

Zhang Rui — full company profile →

Who can join

Adults 18 to 75, any sex, with Almost-cCR or Surgery. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is evaluate the effect of two different surgical treatment on lower rectal cancer after almost clinical complete response(almost-cCR). All almost clinical complete response(almost-cCRs) were entered into two groups randomly. The estimated sample size of the minimal operation group was 221, and 221 in the Mile's group. Three years' progression-free survival(PFS) and overall survival(OS) were compared.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03431428 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zhang Rui
Last refreshed: 13 February 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03431428.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing